ArticleACS omega2026
Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapamycin (RAP) is a macrolide antibiotic with potent immunomodulatory and anticancer properties, but its clinical use is hindered by poor solubility, chemical instability, and limited bioavailability. The aim of this study was the development of PEG-coated albumin nanoparticles for delivering rapamycin and maintaining its biological activity after encapsulation. Rapamycin-loaded albumin nanoparticles were prepared by desolvation of an aqueous solution of the protein with ethanol and subsequent coating with PEG 35,000. The resulting nanoparticles (NPA-RAP) displayed adequate physicochemical properties for intravenous delivery, including sizes within the tumor-targeting range (150-200 nm), low polydispersity (<0.2), and negative zeta potential (∼-30 mV). PEGylation and surface charge ensured short-term stability, while encapsulation efficiency exceeded 70%, with sustained biphasic release (40% over 24 h) well described by the Weibull model. In vitro, NPA-RAP showed cytotoxicity in MCF-7 breast cancer cells comparable to free rapamycin but with lower IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.